Effect of Selected Crystalloid and Colloid Solutions on Coagulation Status Evaluated by Rotational Thromboelastometry and Platelet Function Analyser: An in vitro Study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F25%3A10487493" target="_blank" >RIV/00064203:_____/25:10487493 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/25:10487493

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=I2h9P~IBjt" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=I2h9P~IBjt</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1159/000541772" target="_blank" >10.1159/000541772</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of Selected Crystalloid and Colloid Solutions on Coagulation Status Evaluated by Rotational Thromboelastometry and Platelet Function Analyser: An in vitro Study

Popis výsledku v původním jazyce

Introduction: Crystalloid and colloid solutions commonly used in intensive and perioperative care can affect haemocoagulation status. This in vitro study assessed the impact of Plasma-Lyte, albunorm 5%, and Gelaspan 4% solutions on primary and secondary haemostasis using rotational thromboelastometry and platelet function analyser. Methods: In this prospective study, we examined blood samples from 20 healthy volunteers using rotational thromboelastometry and platelet function analyser. Simultaneously, we analysed the blood samples subjected to 10% dilution using Plasma-Lyte, albunorm 5%, and Gelaspan 4% solutions. Results: Compared to controls, Plasma-Lyte shortened EXTEM-CT (p = 0.005) and reduced FIBTEM-MCF (p = 0.017). albunorm 5% prolonged EXTEM-CFT (p = 0.001), decreased EXTEM-alpha (p &lt; 0.001) and MCF in EXTEM, INTEM, and FIBTEM tests (p &lt; 0.001, p = 0.038, p = 0.001, respectively), along with MCE in the PLTEM test (p &lt; 0.001). Gelaspan 4% also prolonged EXTEM-CFT (p &lt; 0.001), decreased EXTEM-alpha (p &lt; 0.001) and MCF in EXTEM, INTEM, and FIBTEM tests (p &lt; 0.001, p &lt; 0.001, p = 0.009, respectively), along with MCE in the PLTEM test (p &lt; 0.001). Gelaspan 4% also reduced EXTEM-CT (p = 0.021). All solution prolonged CT in PFA Col/ADP (p = 0.003 for Plasma-Lyte, p &lt; 0.001 for albunorm and Gelaspan) and albunorm 5% also prolonged CT in Col/Epi (p = 0.003). Conclusion: Plasma-Lyte had the least effect on secondary haemostasis, whereas albunorm 5% had the least effect among colloids. Gelaspan 4% adversely affected the propagation phase of coagulation, maximal strength and elasticity of the coagulum, and the level of functional fibrinogen. All solutions adversely affected platelet function in primary haemostasis, with Plasma-Lyte showing the least effect.

Název v anglickém jazyce

Effect of Selected Crystalloid and Colloid Solutions on Coagulation Status Evaluated by Rotational Thromboelastometry and Platelet Function Analyser: An in vitro Study

Popis výsledku anglicky

Introduction: Crystalloid and colloid solutions commonly used in intensive and perioperative care can affect haemocoagulation status. This in vitro study assessed the impact of Plasma-Lyte, albunorm 5%, and Gelaspan 4% solutions on primary and secondary haemostasis using rotational thromboelastometry and platelet function analyser. Methods: In this prospective study, we examined blood samples from 20 healthy volunteers using rotational thromboelastometry and platelet function analyser. Simultaneously, we analysed the blood samples subjected to 10% dilution using Plasma-Lyte, albunorm 5%, and Gelaspan 4% solutions. Results: Compared to controls, Plasma-Lyte shortened EXTEM-CT (p = 0.005) and reduced FIBTEM-MCF (p = 0.017). albunorm 5% prolonged EXTEM-CFT (p = 0.001), decreased EXTEM-alpha (p &lt; 0.001) and MCF in EXTEM, INTEM, and FIBTEM tests (p &lt; 0.001, p = 0.038, p = 0.001, respectively), along with MCE in the PLTEM test (p &lt; 0.001). Gelaspan 4% also prolonged EXTEM-CFT (p &lt; 0.001), decreased EXTEM-alpha (p &lt; 0.001) and MCF in EXTEM, INTEM, and FIBTEM tests (p &lt; 0.001, p &lt; 0.001, p = 0.009, respectively), along with MCE in the PLTEM test (p &lt; 0.001). Gelaspan 4% also reduced EXTEM-CT (p = 0.021). All solution prolonged CT in PFA Col/ADP (p = 0.003 for Plasma-Lyte, p &lt; 0.001 for albunorm and Gelaspan) and albunorm 5% also prolonged CT in Col/Epi (p = 0.003). Conclusion: Plasma-Lyte had the least effect on secondary haemostasis, whereas albunorm 5% had the least effect among colloids. Gelaspan 4% adversely affected the propagation phase of coagulation, maximal strength and elasticity of the coagulum, and the level of functional fibrinogen. All solutions adversely affected platelet function in primary haemostasis, with Plasma-Lyte showing the least effect.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30223 - Anaesthesiology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Transfusion Medicine and Hemotherapy

ISSN

1660-3796

e-ISSN

1660-3818

Svazek periodika

52

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

10

Strana od-do

132-141

Kód UT WoS článku

001346207900001

EID výsledku v databázi Scopus

2-s2.0-85208560283